Capital Group Dividend Value ETF (CGDV)
- Previous Close
32.92 - Open
32.88 - Bid 32.95 x 1000
- Ask 32.96 x 3000
- Day's Range
32.85 - 32.98 - 52 Week Range
25.47 - 33.40 - Volume
680,291 - Avg. Volume
1,693,490 - Net Assets 8.26B
- NAV 32.90
- PE Ratio (TTM) 22.88
- Yield 1.53%
- YTD Daily Total Return 10.66%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.33%
Normally, the fund invests at least 80% of its assets in dividend-paying common stocks of larger, more established companies domiciled in the United States with market capitalizations greater than $4.0 billion. It may invest up to 10% of its assets in equity securities of larger companies domiciled outside the United States. The fund is non-diversified.
Capital Group
Fund Family
Large Value
Fund Category
8.26B
Net Assets
2022-02-22
Inception Date
Performance Overview: CGDV
Trailing returns as of 6/7/2024. Category is Large Value.
People Also Watch
Holdings: CGDV
Top 10 Holdings (41.74% of Total Assets)
Sector Weightings
Recent News: CGDV
Research Reports: CGDV
Biogen: Lowering Our Moat Rating to Narrow Based on MS Sales Pressure and Leqembi Uncertainty
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice TargetThe major indices have put recent stock weakness into hibernation, as the S&P 500 (SPX), Nasdaq, and Nasdaq 100 (QQQ) have jumped to all-time highs (ATHs).
The major indices have put recent stock weakness into hibernation, as the S&P 500 (SPX), Nasdaq, and Nasdaq 100 (QQQ) have jumped to all-time highs (ATHs). The false breakout by the SPX was nothing more than a back test of the 50-day average, while pullbacks by the Nasdaq and QQQs represented back tests of breakout zones from mid-May. On Wednesday, the SPX rose 1.2%, and the Nasdaq and QQQs gained 2%. It was clearly a risk-on day, with Technology up 2.3%, Communication Services gaining 1.2%, Industrials adding 1%, and Materials rising 0.7%. Weakness was seen in defensive Utilities, off 0.6%, and Staples, down 0.2%.
Johnson & Johnson: Proteologix Acquisition Yields Promising Early-Stage Immunology Drugs
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
RatingPrice TargetRealty Income Provides Low but Steady Growth for Income-Oriented Investors
Realty Income owns roughly 13,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, gaming, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
RatingPrice Target